Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.120
-0.040 (-1.85%)
At close: Apr 28, 2026, 4:00 PM EDT
2.120
0.00 (0.00%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Protalix BioTherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 52.74 | 53.4 | 65.49 | 47.64 | 38.35 | |
| Revenue Growth (YoY) | -1.23% | -18.47% | 37.48% | 24.22% | -39.03% | |
| Cost of Revenue | 45.88 | 36.7 | 39.3 | 48.42 | 16.35 | |
| Gross Profit | 6.86 | 16.7 | 26.2 | -0.79 | 22 | |
| Selling, General & Admin | 11.68 | 12.19 | 14.96 | 11.71 | 12.73 | |
| Research & Development | 0.68 | 0.59 | 0.78 | 0.52 | 29.73 | |
| Operating Expenses | 12.36 | 12.78 | 15.74 | 12.23 | 42.46 | |
| Operating Income | -5.5 | 3.92 | 10.46 | -13.01 | -20.46 | |
| Interest Expense | -1.19 | -1.06 | -3.18 | -2.53 | -7.52 | |
| Interest & Investment Income | 1.08 | 1.3 | 1.29 | 1.15 | 0.4 | |
| EBT Excluding Unusual Items | -5.61 | 4.15 | 8.57 | -14.4 | -27.58 | |
| Pretax Income | -5.61 | 4.15 | 8.57 | -14.4 | -27.58 | |
| Income Tax Expense | 1 | 1.22 | 0.25 | 0.53 | - | |
| Earnings From Continuing Operations | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 | |
| Net Income | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 | |
| Net Income to Common | -6.6 | 2.93 | 8.31 | -14.93 | -27.58 | |
| Net Income Growth | - | -64.73% | - | - | - | |
| Shares Outstanding (Basic) | 79 | 73 | 68 | 48 | 44 | |
| Shares Outstanding (Diluted) | 79 | 81 | 82 | 48 | 44 | |
| Shares Change (YoY) | -3.10% | -1.66% | 70.04% | 9.81% | 51.43% | |
| EPS (Basic) | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 | |
| EPS (Diluted) | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 | |
| EPS Growth | - | -57.71% | - | - | - | |
| Free Cash Flow | -13.63 | 7.39 | -2.47 | -25.63 | -11.74 | |
| Free Cash Flow Per Share | -0.17 | 0.09 | -0.03 | -0.53 | -0.27 | |
| Gross Margin | 13.01% | 31.27% | 40.00% | -1.65% | 57.37% | |
| Operating Margin | -10.43% | 7.33% | 15.97% | -27.32% | -53.36% | |
| Profit Margin | -12.52% | 5.49% | 12.69% | -31.33% | -71.92% | |
| Free Cash Flow Margin | -25.84% | 13.84% | -3.77% | -53.80% | -30.62% | |
| EBITDA | -4.04 | 5.22 | 11.65 | -11.93 | -19.34 | |
| EBITDA Margin | -7.65% | 9.78% | 17.79% | -25.04% | -50.44% | |
| D&A For EBITDA | 1.47 | 1.3 | 1.19 | 1.09 | 1.12 | |
| EBIT | -5.5 | 3.92 | 10.46 | -13.01 | -20.46 | |
| EBIT Margin | -10.43% | 7.33% | 15.97% | -27.32% | -53.36% | |
| Effective Tax Rate | - | 29.42% | 2.96% | - | - | |
| Revenue as Reported | 52.74 | 53.4 | 65.49 | 47.64 | 38.35 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.